C19orf33 is a long non-coding RNA with emerging roles in cancer biology and immune-inflammatory conditions. In breast cancer, C19orf33 is significantly upregulated in multifocal/multicentric breast cancer (MMBC) compared to unifocal disease, suggesting it may function as a biomarker for MMBC 1. In pancreatic ductal adenocarcinoma (PDAC), C19orf33 is upregulated in tumor samples and shows strong correlative expression with ITGB4 in ductal cells; both genes are downregulated following chemotherapeutic treatment, implicating them in metastatic promotion 2. C19orf33 was identified as a hub gene in urothelial protein-protein interaction networks associated with interstitial cystitis/bladder pain syndrome 3. In acute myeloid leukemia, C19orf33 participates in differentially regulated gene networks distinguishing azacitidine-sensitive from resistant cell lines, suggesting involvement in chemotherapy resistance mechanisms 4. In head and neck squamous cell carcinoma, C19orf33 emerged as a prognostically important switch gene for distant metastasis 5. Additionally, genetic variants affecting C19orf33 expression through trans-eQTL mechanisms were associated with mean platelet volume, indicating roles in hematologic phenotypes 6. In aggressive breast cancer phenotypes, C19orf33 participates in co-expression networks associated with metastatic potential 7. These findings suggest C19orf33 functions in cancer progression, metastasis, and chemotherapy response across multiple tissue types, positioning it as a potential diagnostic and therapeutic target.